According to Zhitong Finance App, China Bolton (03318.HK) announced that on November 13, 2026, Shenzhen Bolton, an indirect wholly-owned subsidiary of the Company, entered into a capital injection agreement with the target company Shandong Ganghong Biotechnology Co., Ltd. and the target shareholders (i.e. Wei Jie and Song Chuanlan). Based on this, Shenzhen Bolton conditionally agreed to inject capital into the target company to acquire 49% of the target company's shares at a cost of RMB 160 million (equivalent to about HK$186 million).

According to Zhitong Finance App, China Bolton (03318.HK) announced that on November 13, 2026, Shenzhen Bolton, an indirect wholly-owned subsidiary of the Company, entered into a capital injection agreement with the target company Shandong Ganghong Biotechnology Co., Ltd. and the target shareholders (i.e. Wei Jie and Song Chuanlan). Based on this, Shenzhen Bolton conditionally agreed to inject capital into the target company to acquire 49% of the target company's shares at a cost of RMB 160 million (equivalent to about HK$186 million).